Cancer Research and Treatment10.4143/crt.2017.5982019511128-140Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer PatientsLing Deng, Xuehua Zhu, Yun Sun, Jiemin Wang, Xiaorong Zhong, Jiayuan Li, Min Hu, Hong Zheng,,
PLOS ONE10.1371/journal.pone.02034952018139e0203495Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patientsGuoli Li, Xinwu Guo, Ming Chen, Lili Tang, Hui Jiang, Julia X. Day, Yueliang Xie, Limin Peng, Xunxun Xu, Jinliang Li, Shouman Wang, Zhi Xiao, Lizhong Dai, Jun Wang
Experimental Dermatology10.1111/j.1600-0625.2009.01056.x2010198e222-e227Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutationsChristian Hafner, Michael Landthaler, Thomas Vogt
Current Breast Cancer Reports10.1007/s12609-016-0215-620168273-79Defining the Prognostic and Predictive Role of PIK3CA Mutations: Sifting Through the Conflicting DataSana Al-Sukhun, Isam Lataifeh, Rajaa Al-Sukhun,,
OncoTargets and Therapy10.2147/ott.s601152014543PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysisZhi-Ming Shao, Yi-Rong Liu, Yi-Zhou Jiang, Ke-Da Yu, Wen-Jia Zuo
Breast Cancer Online10.1017/s14709031060055912006971-4Functional characterization of PIK3CA as a breast cancer oncogene Review of: 1. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells 2. The oncogenic properties of mutant p110 alpha and p110 beta phosphatidylinositol 3-kinases in human mammary epithelial cellsH. L. Bennett, R. J. Daly
Annals of Oncology10.1093/annonc/mdy272.289201829suppl_8299PThe prevalence of PIK3CA mutations in HR+/HER2– metastatic breast cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)K Wan, Y A Wang, M Kaper, M Fritzemeier, N Babbar
Breast Cancer Research10.1186/bcr36052014161PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataDimitrios Zardavas, Wayne A Phillips, Sherene Loi,,
The Breast10.1016/s0960-9776(19)30338-8201944S97The BRCA1/2 mutations and ER status in Chinese patients with synchronous bilateral breast cancerL. Huang,
European Journal of Cancer10.1016/j.ejca.2012.06.014201248152293-2299Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancerM. Arnedos, V. Scott, B. Job, J. De La Cruz, F. Commo, M.C. Mathieu, R. Wolp-Diniz, C. Richon, M. Campone, T. Bachelot, F. Dalenc, P. Dessen, L. Lacroix, V. Lazar, J.C. Soria, S. Delaloge, F. Andre,